Edwards Lifesciences' 22.1% Yearly Gain Driven by TMTT Growth, But Premium Valuation and Regulatory Risks Loom

What happened

Edwards Lifesciences shares have risen 22.1% over the past year, fueled by strong adoption of TMTT technologies like PASCAL and EVOQUE, as highlighted in a recent Zacks article. The DeepValue report confirms this momentum, noting Q3 2025 TAVR sales grew 12.4% YoY and TMTT is on track for $500-530M in 2025, aligning with raised guidance. However, the report underscores that these positives are already reflected in the stock's premium valuation of 28-29x 2026 EPS, leaving limited upside without flawless execution. Critical risks persist, including antitrust setbacks like the FTC blocking the JenaValve acquisition and recurring device recalls that could erode clinical confidence. Market sentiment has shifted towards optimism, but investors must assess whether growth can sustain amid regulatory headwinds and competitive pressure.

Implication

The stock's climb validates Edwards' execution on TAVR and TMTT, but at a P/E of 36.2x, further gains hinge on TMTT hitting $740-780M in 2026 and TAVR maintaining 6-8% growth. Any misstep, such as TAVR growth falling below 4% or a major recall, could trigger a drop toward the bear case of $70, eroding margin of safety. Monitoring quarterly TAVR trends, TMTT adoption rates, and regulatory developments over the next 6-12 months is crucial to gauge sustainability. Given the WAIT rating, it's prudent to avoid new positions until shares retreat below the attractive entry of $72 or clear evidence emerges of growth accelerating without new risks. Long-term, Edwards remains a quality business, but current pricing demands perfection that may not materialize in a volatile regulatory environment.

Thesis delta

The positive news reinforces the growth narrative but does not alter the core investment thesis, which already priced in strong TAVR and TMTT performance. No shift is warranted; the stock remains fully valued at ~$84, and the WAIT rating stands as valuation offers little buffer against execution or regulatory slippage. Investors should adhere to this stance until either price dips below $72 or growth accelerates beyond guidance without escalating risks.